The fact that Mcl-1 has been reported to be the primary protein responsible for the resistance to ABT 737 in small cell lung cancer and myeloid leukaemia [20, 21] has also suggested that reduction in Mcl-1 would be an important cancer therapeutic target. This evidence concerns the gene MCL1 and myeloid leukemia.